Gastrointestinal Stromal Tumors Therapeutics Market 2028 By Route Of Administration, Distribution Channel and Geography | The Insight Partners

Gastrointestinal Stromal Tumors Therapeutics Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Route Of Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00005556 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Gastrointestinal Stromal Tumors Therapeutics Market - By Route Of Administration
1.3.2 Gastrointestinal Stromal Tumors Therapeutics Market - By Distribution Channel
1.3.3 Gastrointestinal Stromal Tumors Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
7.1. OVERVIEW
7.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
7.3. ORAL
7.3.1. Overview
7.3.2. Oral Market Forecast and Analysis
7.4. PARENTERAL
7.4.1. Overview
7.4.2. Parenteral Market Forecast and Analysis
8. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.1.2 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.1.3 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.1.4 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Gastrointestinal Stromal Tumors Therapeutics Market
9.1.5.1.1 United States Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.1.5.1.2 United States Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.1.5.2 Canada Gastrointestinal Stromal Tumors Therapeutics Market
9.1.5.2.1 Canada Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.1.5.2.2 Canada Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.1.5.3 Mexico Gastrointestinal Stromal Tumors Therapeutics Market
9.1.5.3.1 Mexico Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.1.5.3.2 Mexico Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.2.2 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.2.3 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.2.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.1.1 Germany Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.1.2 Germany Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.2 France Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.2.1 France Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.2.2 France Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.3 Italy Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.3.1 Italy Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.3.2 Italy Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.4 Spain Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.4.1 Spain Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.4.2 Spain Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.5 United Kingdom Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.5.1 United Kingdom Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.5.2 United Kingdom Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.3.2 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.3.4 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.1.1 Australia Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.1.2 Australia Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.2 China Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.2.1 China Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.2.2 China Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.3 India Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.3.1 India Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.3.2 India Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.4 Japan Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.4.1 Japan Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.4.2 Japan Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.5 South Korea Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.5.1 South Korea Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.5.2 South Korea Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.4.2 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.4.4 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Gastrointestinal Stromal Tumors Therapeutics Market
9.4.5.1.1 South Africa Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.4.5.1.2 South Africa Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.4.5.2 Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market
9.4.5.2.1 Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.4.5.2.2 Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.4.5.3 U.A.E Gastrointestinal Stromal Tumors Therapeutics Market
9.4.5.3.1 U.A.E Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.4.5.3.2 U.A.E Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.5.2 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.5.4 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Gastrointestinal Stromal Tumors Therapeutics Market
9.5.5.1.1 Brazil Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.5.5.1.2 Brazil Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.5.5.2 Argentina Gastrointestinal Stromal Tumors Therapeutics Market
9.5.5.2.1 Argentina Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.5.5.2.2 Argentina Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. AROG PHARMACEUTICALS, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BOSTON BIOMEDICAL
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CELLDEX THERAPEUTICS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. F. HOFFMANN-LA ROCHE LTD
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. IMMUNICUM AB.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NATCO PHARMA LIMITED
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. AROG Pharmaceuticals, INC.
2. Bayer AG
3. Boston Biomedical
4. Celldex Therapeutics
5. F. Hoffmann-La Roche Ltd
6. Immunicum AB.
7. NATCO Pharma Limited
8. Novartis AG
9. Pfizer Inc.
10. Sun Pharmaceutical Industries Ltd.
TIPRE00005556
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount